Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,002.95
+2.16 (+0.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
31
32
Next >
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
February 01, 2023
For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.
Via
InvestorPlace
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
February 01, 2023
Via
Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
January 30, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
January 19, 2023
Via
Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
January 11, 2023
Via
Benzinga
Regeneron Reveals An Early Cut Data From Follicular Lymphoma Study At ASH Meeting
December 13, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
January 30, 2023
Via
Benzinga
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
January 23, 2023
It's difficult to imagine a future where healthcare isn't in high demand.
Via
The Motley Fool
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Via
Benzinga
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
January 17, 2023
Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
January 20, 2023
Via
Benzinga
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
January 13, 2023
Sharp Tesla price cuts and some notable earnings were in focus.
Via
Investor's Business Daily
Check Out What Whales Are Doing With REGN
January 10, 2023
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange...
Via
Benzinga
Check Out What Whales Are Doing With REGN
January 09, 2023
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 30 strange...
Via
Benzinga
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin
January 09, 2023
Regeneron Pharmaceuticals says sales of linchpin Eylea drug have been negatively impacted rival drug Avastin. REGN stock plunged on the news.
Via
Investor's Business Daily
What This Drug News Could Mean for Sanofi Shareholders
January 08, 2023
This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.
Via
The Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
January 06, 2023
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.
Via
InvestorPlace
CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker
January 06, 2023
Via
Benzinga
3 Growth Stocks That Could Rocket Higher in 2023
January 06, 2023
Upcoming binary events could push these stocks to new all-time highs.
Via
The Motley Fool
Jim Cramer Says He's 'Still Feeling Good' About These 5 Stocks From 'Mutilated' Nasdaq
January 05, 2023
Prominent market commentator Jim Cramer has recommended five stocks from the Nasdaq Index that he believes could be decent additions to investors’ portfolios.
Via
Benzinga
2 Unstoppable Dividend Growth Stocks to Buy in 2023 and Beyond
December 29, 2022
Nothing is more reassuring to an income investor than a boost to the dividend.
Via
The Motley Fool
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
December 24, 2022
For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while.
Via
The Motley Fool
Tuesday Talk: Where is Santa?
December 20, 2022
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found.
Via
Talk Markets
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
December 19, 2022
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.
Via
Talk Markets
2 Best Biotech Stocks to Buy Right Now
December 16, 2022
Demand for medicines and vaccines has nowhere to go but up over the long run.
Via
The Motley Fool
Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis
December 15, 2022
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.